Published in J Neurosurg on August 14, 2020
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg (2003) 3.91
Patterns of care for adults with newly diagnosed malignant glioma. JAMA (2005) 3.08
Achieving the National Quality Forum's "Never Events": prevention of wrong site, wrong procedure, and wrong patient operations. Ann Surg (2007) 3.04
Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg (2009) 2.70
Multi-pulse drug delivery from a resorbable polymeric microchip device. Nat Mater (2003) 2.65
Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys (2013) 2.28
Seizure control for patients undergoing meningioma surgery. World Neurosurg (2012) 2.19
Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival. Clinical article. J Neurosurg (2010) 2.11
Preoperative charlson comorbidity score predicts postoperative outcomes among older intracranial meningioma patients. World Neurosurg (2011) 2.09
Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg (2009) 1.91
Central nervous system cancers. J Natl Compr Canc Netw (2013) 1.82
Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme. Neurosurgery (2009) 1.79
Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery (2008) 1.72
Multiple resections for patients with glioblastoma: prolonging survival. J Neurosurg (2012) 1.72
Disparities in access to neuro-oncologic care in the United States. Arch Surg (2010) 1.67
Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells. Clin Cancer Res (2012) 1.67
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol (2005) 1.63
Targeted therapy for brain tumours. Nat Rev Drug Discov (2004) 1.63
Teaching hospital status and operative mortality in the United States: tipping point in the volume-outcome relationship following colon resections? Arch Surg (2010) 1.61
Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats. J Neurosurg (2002) 1.54
Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro Oncol (2013) 1.51
Pilocytic and pilomyxoid hypothalamic/chiasmatic astrocytomas. Neurosurgery (2004) 1.47
Postoperative mortality after surgery for brain tumors by patient insurance status in the United States. Arch Surg (2012) 1.47
Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project. J Neurosurg (2003) 1.47
Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf (2007) 1.46
Improvement in the standard treatment for experimental glioma by fusing antibody Fc domain to endostatin. J Neurosurg (2011) 1.42
Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers. Invest New Drugs (2004) 1.40
Outcome and cost of craniotomy performed to treat tumors in regional academic referral centers. Neurosurgery (2003) 1.39
Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol (2008) 1.31
Advancing the field of drug delivery: taking aim at cancer. Cancer Cell (2003) 1.28
Correlation of preoperative depression and somatic perception scales with postoperative disability and quality of life after lumbar discectomy. J Neurosurg Spine (2011) 1.26
Supratentorial glioblastoma multiforme: the role of surgical resection versus biopsy among older patients. Ann Surg Oncol (2010) 1.24
Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells. Mol Cancer Ther (2009) 1.18
Central nervous system cancers. J Natl Compr Canc Netw (2011) 1.13
Interstitial chemotherapy for malignant gliomas: the Johns Hopkins experience. J Neurooncol (2006) 1.12
Local delivery of doxorubicin for the treatment of malignant brain tumors in rats. Anticancer Res (2005) 1.11
In vitro drug response and molecular markers associated with drug resistance in malignant gliomas. Clin Cancer Res (2006) 1.10
A novel rat model for the study of intraosseous metastatic spine cancer. J Neurosurg Spine (2005) 1.08
Everolimus for astrocytomas in tuberous sclerosis. Lancet (2013) 1.07
Clostridium perfringens enterotoxin as a novel-targeted therapeutic for brain metastasis. Cancer Res (2007) 1.07
Local drug delivery to the brain. Adv Drug Deliv Rev (2002) 1.07
Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. Cancer Chemother Pharmacol (2007) 1.05
Factors involved in maintaining prolonged functional independence following supratentorial glioblastoma resection. Clinical article. J Neurosurg (2010) 1.02
Use of the video telescope operating monitor (VITOM) as an alternative to the operating microscope in spine surgery. Spine (Phila Pa 1976) (2012) 1.01
Variations in referral patterns to high-volume centers for pancreatic cancer. J Am Coll Surg (2009) 1.01
In vivo release from a drug delivery MEMS device. J Control Release (2004) 1.01
Local treatment of malignant brain tumors using implantable chemotherapeutic polymers. J Natl Compr Canc Netw (2005) 1.01
Perioperative and long-term outcomes from the management of parasagittal meningiomas invading the superior sagittal sinus. Neurosurgery (2010) 1.00
Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model. Neurosurgery (2010) 1.00
Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management. Cancer Invest (2004) 0.98
Intracranial microcapsule drug delivery device for the treatment of an experimental gliosarcoma model. Biomaterials (2011) 0.98
Loss of PTEN is not associated with poor survival in newly diagnosed glioblastoma patients of the temozolomide era. PLoS One (2012) 0.97
The surgical bed after BCNU polymer wafer placement for recurrent glioma: serial assessment on CT and MR imaging. AJR Am J Roentgenol (2003) 0.96
Polymeric nanoparticles for nonviral gene therapy extend brain tumor survival in vivo. ACS Nano (2015) 0.96
Prognosis of patients with multifocal glioblastoma: a case-control study. J Neurosurg (2012) 0.95
Survival and prognostic factors of anaplastic gliomas. Neurosurgery (2013) 0.95
The efficacy of carmustine wafers for older patients with glioblastoma multiforme: prolonging survival. Neurol Res (2011) 0.93
The effect of centralization of caseload for primary brain tumor surgeries: trends from 2001-2007. Acta Neurochir (Wien) (2012) 0.91
Persistent outpatient hyperglycemia is independently associated with survival, recurrence and malignant degeneration following surgery for hemispheric low grade gliomas. Neurol Res (2009) 0.91
A thermal gel depot for local delivery of paclitaxel to treat experimental brain tumors in rats. J Neurosurg (2010) 0.91
Polymer delivery of camptothecin against 9L gliosarcoma: release, distribution, and efficacy. J Neurooncol (2002) 0.91
Resorbable polymer microchips releasing BCNU inhibit tumor growth in the rat 9L flank model. J Control Release (2007) 0.90
Prognostic significance of contrast-enhancing anaplastic astrocytomas in adults. J Neurosurg (2010) 0.90
Predictors of inpatient death and complications among postoperative elderly patients with metastatic brain tumors. Ann Surg Oncol (2010) 0.89
Necrotizing enterocolitis in 20,822 infants: analysis of medical and surgical treatments. Clin Pediatr (Phila) (2010) 0.89
Surgical intervention for thoracic outlet syndrome improves patient's quality of life. J Vasc Surg (2009) 0.89
Deep venous thrombosis and pulmonary embolisms in adult patients undergoing craniotomy for brain tumors. Neurol Res (2012) 0.88
Complications and death among elderly patients undergoing pituitary tumour surgery. Clin Endocrinol (Oxf) (2010) 0.88
In vivo delivery of BCNU from a MEMS device to a tumor model. J Control Release (2005) 0.88
Pericytic-like angiotropism of glioma and melanoma cells. Am J Dermatopathol (2002) 0.88
Association of preoperative depression and survival after resection of malignant brain astrocytoma. Surg Neurol (2008) 0.88
Local delivery of minocycline and systemic BCNU have synergistic activity in the treatment of intracranial glioma. J Neurooncol (2003) 0.87
Regression of intracranial meningioma following intratumoral hemorrhage. J Clin Neurosci (2009) 0.87
A safety and efficacy study of local delivery of interleukin-12 transgene by PPC polymer in a model of experimental glioma. Anticancer Drugs (2008) 0.86
Intracranial-pressure monitoring in traumatic brain injury. N Engl J Med (2013) 0.86
Preservation of glial cytoarchitecture from ex vivo human tumor and non-tumor cerebral cortical explants: A human model to study neurological diseases. J Neurosci Methods (2007) 0.86
Central nervous system cancers: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2005) 0.85
Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: a novel treatment for experimental malignant glioma. Neurosurgery (2003) 0.85
Delayed onset of paresis in rats with experimental intramedullary spinal cord gliosarcoma following intratumoral administration of the paclitaxel delivery system OncoGel. J Neurosurg Spine (2012) 0.84
A novel intramedullary spinal cord tumor model: functional, radiological, and histopathological characterization. J Neurosurg Spine (2005) 0.84
Local delivery of interleukin-2 and adriamycin is synergistic in the treatment of experimental malignant glioma. J Neurooncol (2005) 0.84
Comparison of survival between cerebellar and supratentorial glioblastoma patients: surveillance, epidemiology, and end results (SEER) analysis. Neurosurgery (2013) 0.84
Hypertonic saline ameliorates cerebral edema associated with experimental brain tumor. J Neurosurg Anesthesiol (2002) 0.84
Factors associated with survival for patients with glioblastoma with poor pre-operative functional status. J Clin Neurosci (2013) 0.84
Risk of surgical site infection in 401 consecutive patients with glioblastoma with and without carmustine wafer implantation. Neurol Res (2015) 0.84
Local intracerebral administration of Paclitaxel with the paclimer delivery system: toxicity study in a canine model. J Neurooncol (2006) 0.83
Does 30-day readmission affect long-term outcome among glioblastoma patients? Neurosurgery (2014) 0.83
Polilactofate microspheres for Paclitaxel delivery to central nervous system malignancies. Clin Cancer Res (2003) 0.83
Local delivery of antineoplastic agents by controlled-release polymers for the treatment of malignant brain tumours. Expert Opin Biol Ther (2005) 0.82
Reduction of cerebrospinal fluid rhinorrhea after vestibular schwannoma surgery by reconstruction of the drilled porus acusticus with hydroxyapatite bone cement. J Neurosurg (2007) 0.82
Immediate Single-Stage Cranioplasty Following Calvarial Resection for Benign and Malignant Skull Neoplasms Using Customized Craniofacial Implants. J Craniofac Surg (2015) 0.82
The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas. Cancer Chemother Pharmacol (2012) 0.82
Growth properties of SF188/V+ human glioma in rats in vivo observed by magnetic resonance imaging. J Neurooncol (2012) 0.81
Local delivery of rapamycin: a toxicity and efficacy study in an experimental malignant glioma model in rats. Neuro Oncol (2011) 0.81
Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model. Cancer Chemother Pharmacol (2013) 0.81